Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603148 · ClinicalTrials.gov registry record
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications
A clinical trial of Genetic Polymorphism, sponsored by Vanderbilt University.
- Completed
- Registry status
- 475
- Enrollment target
- 1
- Study location
NCT00603148 is a study of Genetic Polymorphism that has completed, run by Vanderbilt University. The registered enrollment target is 475 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00603148, a study of Genetic Polymorphism, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 475 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will begin to define these critical determinants for patients undergoing procedures in the hybrid interventional cardiology/cardiac surgery suite. In future studies, the data obtained from this study will be used to prospectively stratify patients in terms of bleeding verses thrombotic risk to design studies to optimize anticoagulation and anti-platelet therapies in the hybrid setting.
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603148
The ClinicalTrials.gov registry entry for NCT00603148 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genetic Polymorphism appearing as the primary indexed condition, and to 0 interventions.
NCT00603148 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00603148 about?
NCT00603148 is a clinical study titled "The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications". This study will begin to define these critical determinants for patients undergoing procedures in the hybrid interventional cardiology/cardiac surgery suite. In future studies, the data obtained from this study will be used to prospectively stratify patients in terms of bleeding verses thrombotic ri...
What is the current status of trial NCT00603148?
This trial is currently completed. The enrollment target is 475 participants. The study started on 2006-09. Estimated completion is 2010-02.
What conditions does trial NCT00603148 study?
This clinical trial studies the following conditions: Genetic Polymorphism.
Who is sponsoring clinical trial NCT00603148?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00603148 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Polymorphism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.